Lymphoma

Pages Tagged with "Lymphoma"

Patient thriving after experimental lymphoma treatment
Renee Bentson wasn’t accustomed to feeling tired. Or ill. “I’ve always been a healthy person,” said the Covina, California, mother of five and gym enthusiast, 71. “I would run seven...
City of Hope Ranks Among Nation’s Top 10 Best Hospitals for Cancer
City of Hope was recognized as the eighth “Best Hospital” for cancer in the nation, according to U.S. News & World Report’s 2023-24 Best Hospitals: Specialty Ranking. This marks the...
U.S. News & World Report Ranks City of Hope Among Nation's Top 10 Best Hospitals for Cancer
LOS ANGELES — City of Hope, one of the largest cancer research and treatment organizations in the United States, was recognized as the eighth “Best Hospital” for cancer in the...
Non-Hodgkin lymphoma survivor finds a new purpose
June is National Cancer Survivors Month, a perfect time to meet some of the patients who have been through disease and come out on the other side with a renewed...
Immunotherapy trial 'great news' for advanced lymphoma patients
A Phase 3 clinical trial has demonstrated that patients with advanced (Stage 3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, combined with...
Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy
Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023...
Powerful new therapy doubles treatment targets
For many years, chemotherapy has been the standard treatment for most cancers. While these drugs are often effective, they can come with a host of side effects. Thankfully, City of...
City of Hope Trial Led to New Bispecific Antibody for Lymphoma
Mosunetuzumab is a bispecific antibody — a new class of fixed-duration cancer immunotherapy that acts on two cellular targets simultaneously. Mosunetuzumab helps T cells target cancer cells by bridging CD3...
Leading-edge researcher meets ‘old school’ physician
Marie Palomino ignored the knot on her neck for nearly a year. Until she couldn’t. Traveling through Europe in June 2022, the 64-year-old interpreter and public school teacher began to...
Lymphoma patient thrives after CAR T treatment
Mutua Munavu is a can-do guy in a can-do job. He’s an engineer at Boeing, working in customer support. “We’re the ones who keep the planes flying,” he says. He...